Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2017-01-25 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
IRANNOTICE
Regulatory Filings Classification · 100% confidence The document is a short notice referencing a disclosure made in the company's Annual Report on Form 20-F for the year ended December 31, 2016. It states that the disclosure was filed with the SEC on January 25, 2017. The document itself does not contain the full annual report or substantive financial data but serves as a notification of the filing. The length is only 1171 characters, indicating it is a brief notice rather than a full report. Therefore, according to the MENU VS MEAL RULE, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory notice about a report filing, not the report itself.
2017-01-25 English
20-F
Annual Report FY 2016
2017-01-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It references "Excerpts from Novartis Annual Report 2016" as an exhibit but does not contain the full annual report itself. The document length is only 1577 characters, indicating it is a brief filing rather than a full report. The presence of signatures and the nature of Form 6-K filings suggest this is a regulatory filing providing updates or excerpts rather than the full annual report. According to the rules, such filings that do not contain full financial statements but provide excerpts or updates are classified as Regulatory Filings (RNS).
2017-01-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references exhibits including a Financial Report for Q4 2016 and an Interim Financial Report, but the document itself is short (1485 characters) and does not contain the actual financial data or detailed financial statements. Instead, it appears to be a cover or transmittal report indicating that these reports are being furnished. According to the 'MENU VS MEAL' rule, such a short document that references attached reports without including substantive financial data should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2017-01-25 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of a media release providing an update on clinical trial results for a drug (pegpleranib) and related research developments. It includes detailed clinical study information, forward-looking statements, and company background. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing used to disclose material information to the SEC and investors outside of the annual or quarterly report cycle. Given the nature of the document as a Form 6-K with a press release update, it fits best under Regulatory Filings (RNS). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2016-12-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, a foreign private issuer, with the SEC. It is a regulatory filing used to report material information between annual reports (20-F). The content is a media release announcing FDA Priority Review designation for a drug (LEE011) and related clinical trial information. It does not contain financial statements or detailed financial analysis. The document is about a regulatory milestone and clinical trial results, not an earnings release or annual/interim report. It is not a certification or attestation. The length is about 13,670 characters, which is substantial but the content is primarily a press release. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like earnings release or annual report.
2016-11-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.